The 5 analysts offering 12-month price forecasts for Beam Global have a median target of 18.00, with a high estimate of 40.00 and a low estimate of 9.00. The median estimate represents a +168.26% increase from the last price of 6.71.
Analyst Recommendations
The current consensus among 6 polled investment analysts is to Buy stock in Beam Global. This rating has held steady since November, when it was unchanged from a Buy rating.Move your mouse over past months for detail
I am a seasoned financial analyst with a proven track record in evaluating and interpreting market trends, particularly in the realm of publicly traded companies. My expertise extends to meticulous analysis of financial statements, earnings reports, and market indicators. Throughout my career, I have demonstrated a keen understanding of market dynamics, utilizing both quantitative and qualitative methods to form comprehensive assessments. Now, let's delve into the details of the information you provided on Beam Global.
Beam Global Analysis:
Stock Performance:
Current Stock Price (3:59pm ET): $6.71
Today’s Change: +$0.435 (+6.93%)
52-Week Range: $18.89 (High) - $5.00 (Low)
Year-to-Date Change: +61.59%
Price Forecasts:
Analyst Forecasts: Five analysts offer 12-month price forecasts for Beam Global.
Median Target: $18.00
High Estimate: $40.00
Low Estimate: $9.00
Median Estimate Increase: +168.26% from the last price of $6.71
Analyst Recommendations:
Consensus Rating: Buy
Analyst Ratings: The consensus among six polled investment analysts is to buy Beam Global stock. This rating has been steady since November, maintaining a Buy recommendation.
Earnings and Sales Forecasts:
Current Quarter:
Earnings per Share: -$0.28
Sales: $16.0M
Reporting Date: March 27
Growth Metrics:
Quarterly Growth Rates:
Earnings per Share: -7.17%
Sales: -3.23%
Annual Growth Rates:
Earnings per Share: 30.81%
Sales: 151.72%
Historical Estimations:
Estimation Changes: Mouse over a quarter or year to observe how estimates for earnings and sales have changed over time.
In conclusion, Beam Global's stock has experienced significant fluctuations, with a positive trend in year-to-date performance. Analysts project a substantial increase in the stock price over the next 12 months. The consensus recommendation to buy suggests optimism about the company's future. However, it's crucial to monitor the upcoming earnings report on March 27 for a deeper understanding of the company's financial health. The growth metrics provide insights into both short-term and long-term performance, reflecting the dynamic nature of Beam Global's position in the market.
The average price target for Beam Global is $23.50. This is based on 3 Wall Streets Analysts 12-month price targets, issued in the past 3 months. The highest analyst price target is $30.00 ,the lowest forecast is $17.00. The average price target represents 285.25% Increase from the current price of $6.1.
Beam Global shares touched a one-month low after the company reported first-quarter revenue that fell short of analyst expectations. Shares fell as low as $5.53 and were recently down more than 10% to $5.81. The stock is down almost 18% this year. Revenue in the latest quarter climbed to $14.6 million from $13 million.
Based on analyst ratings, Beam Therapeutics's 12-month average price target is $45.56. What is BEAM's upside potential, based on the analysts' average price target? Beam Therapeutics has 44.18% upside potential, based on the analysts' average price target.
The 11 analysts with 12-month price forecasts for Beam Therapeutics stock have an average target of 45.64, with a low estimate of 30 and a high estimate of 80.
According to our Beam price prediction, BEAM price is expected to have a -4.2% decrease and drop as low as by July 27, 2024. Our analysis of the technical indicators suggests that the current market feeling is Bearish Bearish 62%, with a Fear & Greed Index score of 68 (Greed).
The financial health and growth prospects of BEEM, demonstrate its potential to underperform the market. It currently has a Growth Score of B. Recent price changes and earnings estimate revisions indicate this would be a good stock for momentum investors with a Momentum Score of B.
Beem It was acquired by Eftpos from the Commonwealth Bank of Australia, the National Australia Bank, and Westpac in November. At the time, Eftpos said the decision to purchase Beem It for an undisclosed amount was part of its plan to "continue to make inroads in the digital space".
The Beam Therapeutics Inc. stock holds a sell signal from the short-term Moving Average; at the same time, however, there is a buy signal from the long-term average. Since the short-term average is above the long-term average there is a general buy signal in the stock giving a positive forecast for the stock.
Boston Scientific has a consensus rating of Strong Buy which is based on 20 buy ratings, 1 hold ratings and 0 sell ratings. The average price target for Boston Scientific is $86.50. This is based on 21 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
Introduction: My name is Francesca Jacobs Ret, I am a innocent, super, beautiful, charming, lucky, gentle, clever person who loves writing and wants to share my knowledge and understanding with you.
We notice you're using an ad blocker
Without advertising income, we can't keep making this site awesome for you.
+0.435/+6.93%
